ALT5 Sigma Target of Unusually Large Options Trading (NASDAQ:ALTS)

ALT5 Sigma Corporation (NASDAQ:ALTS) was the recipient of unusually large options trading on Wednesday. Stock investors acquired 7,349 call options on the stock. This represents an increase of 53% compared to the average volume of 4,815 call options.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of ALT5 Sigma in a report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of “Sell”.

Hedge Funds Weigh In On ALT5 Sigma

Hedge funds and other institutional investors have recently made changes to their positions in the company. Bridgeway Capital Management LLC raised its holdings in shares of ALT5 Sigma by 9.4% in the second quarter. Bridgeway Capital Management LLC now owns 19,339 shares of the company’s stock valued at $140,000 after acquiring an additional 1,661 shares in the last quarter. Profund Advisors LLC purchased a new position in ALT5 Sigma during the 3rd quarter valued at about $28,000. Arete Wealth Advisors LLC purchased a new position in ALT5 Sigma during the 3rd quarter valued at about $28,000. Evernest Financial Advisors LLC bought a new stake in shares of ALT5 Sigma in the 2nd quarter valued at about $87,000. Finally, Victory Capital Management Inc. purchased a new stake in shares of ALT5 Sigma in the 3rd quarter worth approximately $33,000. Institutional investors own 6.27% of the company’s stock.

ALT5 Sigma Price Performance

Shares of ALTS stock opened at $2.37 on Thursday. The company’s 50-day simple moving average is $1.59 and its two-hundred day simple moving average is $3.84. ALT5 Sigma has a one year low of $1.08 and a one year high of $10.95. The company has a debt-to-equity ratio of 1.45, a quick ratio of 0.88 and a current ratio of 0.88.

ALT5 Sigma (NASDAQ:ALTS) last posted its quarterly earnings results on Monday, January 12th. The company reported $0.29 earnings per share for the quarter. ALT5 Sigma had a negative net margin of 74.89% and a negative return on equity of 179.27%. The firm had revenue of $7.58 million during the quarter.

About ALT5 Sigma

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties.